UPDATE 16 September 25 NOW FULLY BOOKED FOR ATTENDING IN-PERSON. REGISTRATION FOR LIVE STREAM STILL OPEN! Registrations are now full for in-person places but there is still the opportunity to register for the live stream. WAITING LIST for attending in-person – If you would like to be added to a waiting list for an in-person…
Dear MPN Voice community We are inviting people living with Polycythaemia Vera (PV), Essential Thrombocythaemia (ET), or Myelofibrosis (MF) who have received treatment with interferons (Pegasys or BESREMi) to take part in a short, anonymous survey. This important study aims to gather patient experiences during the recent international interferon shortages. The findings will help inform…
Pegylated Interferon Alpha – Supply & Commissioning Update We are very pleased to let you know that the recent shortage of Pegasys interferon has now been resolved, and hospitals are beginning to receive normal supplies again. While Pegasys was in short supply, some people were prescribed a different interferon called Besremi to make sure treatment…
NIHR’s Be Part of Research registry We would like to share this blog with you, from the NIHR Chief Executive Officer and DHSC Chief Scientific Adviser Professor Lucy Chappell, who reflects on the vital role of participants in health and care research and how the NIHR’s Be Part of Research registry will help transform the…
The video of the MPN Voice patients’ virtual forum, held on 3 July 2025, is now available to view. About EHA – a global network actively collaborating with national and international medical associations and societies, advancing haematology education across Europe. The EHA congress is an annual event for clinicians, researchers and other professionals in the…
The vlogcast features Dr Patrick Harrington, Consultant Haematologist, Guy’s & St Thomas’ Hospital, discussing the new study on thrombosis risk in MPN patients using QRISK3 Score. Dr Harrington explains the research the team at Guy’s Hospital have done to see if a new way of assessing patients’ risk of thrombosis (clotting) called QRISK3, could be…
In this vlogcast, Neil shares his personal journey living with a MPN, beginning with his diagnosis of ET in 1994 and progressing to MF in 2023. He speaks candidly about the emotional and physical toll of his MPN, his experiences with treatment, and the ongoing decision-making process around a potential stem cell transplant. Their candid…
FULLY BOOKED! This forum is now fully booked, however, you can add your name to the waiting list, please click on the ‘book here to attend’ button below, or scan the QR code. If we receive any cancellations you will be contacted and offered a place. Friday 7 November 2025, 1 – 5 pm (arrival/registration…
MHRA approves pharmaand GmbH’s Pegasys® (peginterferon alfa-2a) as a treatment for eligible patients with the myeloproliferative neoplasms (MPNs) blood cancers polycythaemia vera (PV) and essential thrombocythaemia (ET) First MHRA approval of an interferon alfa as a monotherapy treatment for adults with essential thrombocythaemia (ET) First MHRA approval of an interferon alfa as a monotherapy treatment…
In this vlogcast, Prof Claire Harrison, Guy’s & St Thomas’ Hospital, London, speaks with Nona about considerations for MPN patients when travelling away from their home city and how to be prepared and cope with change if events cause disruption to travel. Overall, the discussion emphasizes resilience, practical planning and mental well-being to help MPN…